ClinicalTrials.gg
CompletedNCT04876495PROTEINUpdated May 6, 2021

The Effects of Whey, Rice and Potato pRotein isOlates on appeTite rEgulatIoN in Healthy Men

An interventional study of Whey protein isolate and Potato protein isolate in Appetite and General Nutritional Disorders, sponsored by University of Westminster. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-06.

Sponsored by University of Westminster · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 2 years 9 months after the study started (first participant enrolled Jul 2018, registered Apr 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Insulin Resistance with a site in United Kingdom — 7 open to participants now, 9 under way, none of them phase 3. Insulin Resistance · United Kingdom.

Enrollment
74th of 95
12 · median 31
Started
2018
with 12 others
No phase
76 of 106
4 open now
Registered
94th of 106
by date

Among the 106 studies in Insulin Resistance with a site in United Kingdom, this one is the 74th largest by enrollment of the 95 interventional ones that give a count, is one of 13 that started in 2018, is one of 76 with no phase, and was the 94th registered.

Insulin Resistance

2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

7 of the 106 studies in Insulin Resistance with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Insulin Resistance with a site in United Kingdom, or all of them as a file.
02

Study summary

INTRODUCTION: Global protein consumption has been increasing for decades due to changes in socio-economic demographics and consumer trends towards higher protein intake, which may be related to their health benefits in performance nutrition and appetite regulation. The additional intake of protein often occurs in the form of supplements. One of the main ingredients used in sports and weight loss supplements are animal-derived proteins such as whey, which are of high quality, containing all the essential amino acids required in human nutrition with a high absorption rate. However, whey protein has a high environmental footprint, and it may contribute to insulin resistance in susceptible groups (e.g. obese, T2DM, insulin resistant, or those with sarcopenic obesity).

Rice and potato protein isolates are high-quality plant proteins containing all essential amino acids comparably to whey protein. These plant-derived proteins may provide a more sustainable and accessible alternative to animal-derived proteins for appetite regulation and weight management.

Read the detailed description

Intervention study with three treatment groups in a randomised, single-blind, triple crossover design.

Study population: Healthy male participants will receive three different isocaloric and -volumetric protein shakes prepared using whey, rice and potato protein powders on different trial days with at least a one-week washout period apart.

Biological samples (blood and saliva samples) are collected at various time points during the visit. Blood samples are collected at baseline 10 min prior (T-10), then at 30 min (T30), 60 min (T60), 120 min (T120) and at 180 min (T180) after protein shake consumption. Saliva samples are collected at baseline (T-10), then at every 30 minutes following protein shake consumption (T30, T60, T90, T120, T150, T180). In addition, pertinent questionnaires Visual Analogue Scale [VAS] for the assessment of satiety and VAS for the assessment of protein shakes' perception will be collected at T-10, T30, T60, T90, T120, T150, T180 and at T0, respectively

03

Conditions studied

  • Appetite and General Nutritional Disorders

Browse trials for

Keywords

  • nutraceutical
  • protein
  • whey
  • potato protein
  • rice protein
  • appetite
  • satiety
  • insulin
  • glucose
  • appetite hormone
  • GLP-1
  • PYY
  • supplement
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males (18-65 years of age)
  • Healthy subjects

Exclusion criteria

Exclusion Criteria:

  • \<18 years or >65 years
  • Consumption of >21 units of alcohol/week
  • Dieters
  • Any allergies/health issues related to items being ingested
  • Any serious illnesses or those on medication
  • Any illness affecting taste or appetite
  • Any gastrointestinal disorders
  • Any eating disorders
  • Any depression/mental disorders
  • Smoking
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    Whey protein

    Whey protein isolate (45.5g total protein content)

    Dietary Supplement: Whey protein isolate

  • Active comparator
    Potato protein

    Potato protein isolate (45.3g total protein content)

    Dietary Supplement: Potato protein isolate

  • Active comparator
    Rice protein

    Rice protein isolate (45.5g total protein content)

    Dietary Supplement: Rice protein isolate

Interventions

  • Dietary supplementWhey protein isolate

    Instantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake. Other ingredients in the whey protein shake: * Tropicana Trop50 Orange Juice 207mL * Water 43 mL * Sucralose 0.5g The total energy 233.47Kcal. Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study.

  • Dietary supplementPotato protein isolate

    Solanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake. Other ingredients in the potato protein shake: * Tropicana Trop50 Orange Juice 250mL * Sucralose 0.5g The total energy 233.46Kcal Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study.

  • Dietary supplementRice protein isolate

    Oryzatein® Silk 90 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake. Other ingredients in the rice protein shake: * Tropicana Trop50 Orange Juice 183mL * Water 67mL * Sucralose 0.5g The total energy 233.43Kcal Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study.

06

What researchers measure

Primary outcomes

  1. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T-10)

    Marker: glucose (mmol/L)

    Time frame: Glucose measured 10 minutes prior to protein shake consumption

  2. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T30)

    Marker: glucose (mmol/L)

    Time frame: Glucose measured 30 minutes post protein shake consumption

  3. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T60)

    Marker: glucose (mmol/L)

    Time frame: Glucose measured 60 minutes post protein shake consumption

  4. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T120)

    Marker: glucose (mmol/L)

    Time frame: Glucose measured 120 minutes post protein shake consumption

  5. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T180)

    Marker: glucose (mmol/L)

    Time frame: Glucose measured 180 minutes post protein shake consumption

  6. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T-10)

    Marker: insulin (ng/mL)

    Time frame: Insulin measured 10 minutes prior to protein shake consumption

  7. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T30)

    Marker: insulin (ng/mL)

    Time frame: Insulin measured 30 minutes post protein shake consumption

  8. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T60)

    Marker: insulin (ng/mL)

    Time frame: Insulin measured 60 minutes post protein shake consumption

  9. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T120)

    Marker: insulin (ng/mL)

    Time frame: Insulin measured 120 minutes post protein shake consumption

  10. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T180)

    Marker: insulin (ng/mL)

    Time frame: Insulin measured 180 minutes post protein shake consumption

  11. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T-10)

    Markers: glucagon-like peptide 1 (pM)

    Time frame: Glucagon-like peptide 1 measured 10 minutes prior to protein shake consumption

  12. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T30)

    Markers: glucagon-like peptide 1 (pM)

    Time frame: Glucagon-like peptide 1 measured 30 minutes post protein shake consumption

  13. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T60)

    Markers: glucagon-like peptide 1 (pM)

    Time frame: Glucagon-like peptide 1 measured 60 minutes post protein shake consumption

  14. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T120)

    Markers: glucagon-like peptide 1 (pM)

    Time frame: Glucagon-like peptide 1 measured 120 minutes post protein shake consumption

  15. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T180)

    Markers: glucagon-like peptide 1 (pM)

    Time frame: Glucagon-like peptide 1 measured 180 minutes post protein shake consumption

  16. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T-10)

    Markers: peptide tyrosine tyrosine (pg/mL)

    Time frame: Peptide tyrosine tyrosine measured 10 minutes prior to protein shake consumption

  17. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T30)

    Markers: peptide tyrosine tyrosine (pg/mL)

    Time frame: Peptide tyrosine tyrosine measured 30 minutes post protein shake consumption

  18. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T60)

    Markers: peptide tyrosine tyrosine (pg/mL)

    Time frame: Peptide tyrosine tyrosine measured 60 minutes post protein shake consumption

  19. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T120)

    Markers: peptide tyrosine tyrosine (pg/mL)

    Time frame: Peptide tyrosine tyrosine measured 120 minutes post protein shake consumption

  20. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T180)

    Markers: peptide tyrosine tyrosine (pg/mL)

    Time frame: Peptide tyrosine tyrosine measured 180 minutes post protein shake consumption

  21. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T-10)

    Markers: ghrelin (pg/mL)

    Time frame: Ghrelin (pg/mL) measured 10 minutes prior to protein shake consumption

  22. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T30)

    Markers: ghrelin (pg/mL)

    Time frame: Ghrelin (pg/mL) measured 30 minutes post protein shake consumption

  23. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T60)

    Markers: ghrelin (pg/mL)

    Time frame: Ghrelin (pg/mL) measured 60 minutes post protein shake consumption

  24. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T120)

    Markers: ghrelin (pg/mL)

    Time frame: Ghrelin (pg/mL) measured 120 minutes post protein shake consumption

  25. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T180)

    Markers: ghrelin (pg/mL)

    Time frame: Ghrelin (pg/mL) measured 180 minutes post protein shake consumption

  26. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T-10)

    Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)

    Time frame: Visual Analogue Scale for Appetite (VAS-A) collected immediately prior to protein shake consumption

  27. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T30)

    Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)

    Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 30 minutes after protein shake consumption

  28. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T60)

    Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)

    Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 60 minutes after protein shake consumption

  29. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T90)

    Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)

    Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 90 minutes after protein shake consumption

  30. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T120)

    Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)

    Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 120 minutes after protein shake consumption

  31. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T150)

    Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)

    Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 150 minutes after protein shake consumption

  32. To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T180)

    Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)

    Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 180 minutes after protein shake consumption

Secondary outcomes

  1. To assess the perception of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO®

    Subjective analysis including: Visual Analogue Scale for Palatability (VAS-P). Scores range from 0 to 100 (the higher the score the lower the palatability)

    Time frame: VAS for Palatability collected immediately after protein shake consumption

07

Study locations

1 site
  • University of Westminster
    London, Greater London W1W 6UW, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Feb 2021, 30 months.

Of 715 non-industry interventional studies with no phase under Insulin Resistance, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 30 months is above that.

Counting every sponsor, half of 755 studies reached it within 21 months; a quarter within 9 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2021
First posted
May 6, 2021
StartActual
Jul 20, 2018
Primary completionActual
Feb 19, 2021
CompletionActual
Feb 19, 2021
Last update
May 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04876495
Lead sponsor
University of Westminster
Collaborators
Coventry University
Responsible party
Mohammed Gulrez Zariwala (Professor of Translational Physiology, University of Westminster) — Principal investigator
First posted
May 6, 2021
Start date
Jul 20, 2018
Primary completion
Feb 19, 2021
Completion
Feb 19, 2021
Last update
May 6, 2021

Study contacts

Mohammed Gulrez Zariwala, PhD
principal investigator · University of Westminster

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Whey Protein Isolate

Start the discussion